Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q3 2019 · 10-Q
Revenue$44.37M$44.37M+9.0% vs Q3 2018 Net Income-$36.49M-$36.49MN/M vs Q3 2018 EPS Diluted-$0.85-$0.85N/M vs Q3 2018 Operating Income-$34,437,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$14,386,000N/M Margins · derivedOperating margin-77.6%+9.8 pt vs Q3 2018
Net margin-82.2%+51.7 pt vs Q3 2018
ended Sep 30, 2019 · filed Oct 30, 2019 · 30 d after period end